Ohio Mesothelioma Fact Sheet
While mesothelioma is a problem in all states, the specific incident rate for Ohio is 1.1 / 100,000. This is below the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in OH, recent OH mesothelioma-related court cases, mesothelioma specialists in OH and potential asbestos hotspots in Ohio.
Ohio Mesothelioma Info
By clicking on the above tabs, you will find information on mesothelioma specific to the state of Ohio
Ohio Research and Clinical Trials
This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.
Ohio Doctors and Hospitals
This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.
Ohio Cases
This is a partial list of relevant court cases on mesothelioma in your state.
Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.
This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.
Ohio Doctors and Hospitals
This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.
Ohio Cases
This is a partial list of relevant court cases on mesothelioma in your state.
Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.
DiCenzo v. A Best Prods. Co.
No. 2007-1628, SUPREME COURT OF OHIO, June 4, 2008, Submitted, October 22, 2008, Decided
No. 2007-1628, SUPREME COURT OF OHIO, June 4, 2008, Submitted, October 22, 2008, Decided
State ex rel. Pilkington N. Am., Inc. v. Indus. Comm'n
No. 2007-0747, SUPREME COURT OF OHIO, February 26, 2008, Submitted, April 3, 2008, Decided
No. 2007-0747, SUPREME COURT OF OHIO, February 26, 2008, Submitted, April 3, 2008, Decided
State ex rel. Hiatt v. Indus. Comm'n
No. 2002-1116 , SUPREME COURT OF OHIO, April 15, 2003, Submitted , May 16, 2003, Decided
No. 2002-1116 , SUPREME COURT OF OHIO, April 15, 2003, Submitted , May 16, 2003, Decided
State ex rel. Maynard v. Indus. Comm'n
No. 2001-1386 , SUPREME COURT OF OHIO, October 15, 2002, Submitted , December 4, 2002, Decided
No. 2001-1386 , SUPREME COURT OF OHIO, October 15, 2002, Submitted , December 4, 2002, Decided
State ex rel. Hubbard v. Indus. Comm'n of Ohio
No. 2001-0201, SUPREME COURT OF OHIO, June 4, 2002, Submitted , September 25, 2002, Decided
No. 2001-0201, SUPREME COURT OF OHIO, June 4, 2002, Submitted , September 25, 2002, Decided
State ex rel. Liposchak v. Industrial Comm'n
No. 98-2287, SUPREME COURT OF OHIO, June 6, 2000, Submitted , November 15, 2000, Decided
No. 98-2287, SUPREME COURT OF OHIO, June 6, 2000, Submitted , November 15, 2000, Decided
State ex rel. Thompson v. Ohio Edison Co.
No. 96-1715, SUPREME COURT OF OHIO, January 12, 1999, Submitted , April 7, 1999, Decided
No. 96-1715, SUPREME COURT OF OHIO, January 12, 1999, Submitted , April 7, 1999, Decided
Werts v. Goodyear Tire & Rubber Co.
No. 9 1403, COURT OF APPEALS OF OHIO, EIGHTH APPELLATE DISTRICT, CUYAHOGA COUNTY, June 4, 2009, Released
No. 9 1403, COURT OF APPEALS OF OHIO, EIGHTH APPELLATE DISTRICT, CUYAHOGA COUNTY, June 4, 2009, Released
Fagerholm v. GE
No. 91986, COURT OF APPEALS OF OHIO, EIGHTH APPELLATE DISTRICT, CUYAHOGA COUNTY, May 21, 2009, Released
No. 91986, COURT OF APPEALS OF OHIO, EIGHTH APPELLATE DISTRICT, CUYAHOGA COUNTY, May 21, 2009, Released
Oglesby v. CONRAIL Corp.
Court Of Appeals No. E-08-055, COURT OF APPEALS OF OHIO, SIXTH APPELLATE DISTRICT, ERIE COUNTY, March 31, 2009, Decided
Court Of Appeals No. E-08-055, COURT OF APPEALS OF OHIO, SIXTH APPELLATE DISTRICT, ERIE COUNTY, March 31, 2009, Decided
Hospitals and Cancer Centers
We do not have any doctors or cancer centers for this state at the moment.
We do not have any doctors or cancer centers for this state at the moment.
| City | Site |
|
Willington AFB | |
| Ashtabula |
General Tire and Rubber Union Carbide |
| Avon Lake |
Avon Lake Power House Cleveland Illuminating Power Plant |
| Barberton |
Columbia Chemical |
| Brookpark |
Chevrolet Motor Plant |
| Canton |
Champion Paper Pepsi Building |
| Chillicothe |
B&O RR Ohio Atomic Power Plant |
| Circleville |
Circleville Mylar Facilities |
| Cleveland |
Alcoa Plant East 72nd ST. Power Plant Eveready Union Carbide NASA Ohio Clay Company Pennsylvania Rail Road Republic Steel South Euclid Trans Standard Oil |
| Cleves |
Gulf Oil Refinery |
| Clyde |
Whirpeoc Corporation |
| Columbus |
AT&T Columbus Works Plant Chemical Plant Colonial Pipeline Columbus and Southern Power Plant Columbus Works Plant |
| Dayton |
Dayton Forge Dayton Power & Light |
| Duncan |
Sunray Refinery |
| Eastlake |
Eastlake Power House |
| Gallipolis |
Gavin Power Plant |
| Gibsonburg |
Columbia Gas |
| Gypsum |
US Gypsum |
| Hooven |
Gulf Oil Refinery |
| Kanuaga |
Gallipolis Power Plant |
| Lorain |
NASA |
| Middletown |
Armco- Sheffield Steel |
| Oregon |
BP Oil Company Standard Oil Company Standard Oil Refinery Sun Oil Sun Oil Refinery Toledo Edison |
| Parma |
General Motors |
| Perrysburg |
Chrysler Auto Plant |
| Port Clinton |
Celotex |
| Portsmouth |
A.E.C. Plant - Aiken Grinnell Corp |
| Ravenna |
Oak Rubber |
| Rossford |
Libby Owens Ford Glass Plant Union Carbide |
| Toledo |
American Ship Building Gulf Oil Refinery Kaiser Aluminum Shell Oil Company SOHIO British Petroleum Standard Oil Refinery Sunoco Toledo Post Office Toledo University Union Carbide Bunting Brass |
| Warren |
Airco Plant Copperweld Steel GE Plant General Motors Grinnell Corp Ohio Edison Power Plant Packard Electric Republic Steel Republic Steel Plant Thomas Steel Warren General Hospital |
| Waterville |
Johns-Manville |
| Whitehall |
Johns-Manville |
| Wrightsville |
Kialin Power Station |
| Youngtown |
Republic Steel |
Research
Grever, Michael R. Southwest Oncology Group
Grant: 2U10CA004920-34
Grant: 2U10CA004920-34
Abstract: This is a multi-disciplinary collaborative research project directed
toward the development of more effective methods of prevention,
detection, and treatment of human cancer in all its forms. Included in
this project are the following programs: 1) the exploration of new
therapeutic agents through a wide range of neoplastic diseases in Phase
I, II and III studies, and the coincident study of the toxicities of
these agents; 2) the exploration of new combinations of new and old
agents in an effort to exploit synergistic combinations more effectively;
3) the development of multi-modal approaches to specific tumor problems
using surgical, immunological and radiotherapeutic measures in optimal
combinations; 4) the involvement of pertinent basis science disciplines
such as biochemistry, pharmacology, cellular biology and mathematics in
the formulation and execution of specific treatment protocols; 5) the
improvement of cancer care in the community at large by using these
programs in the educational effort directed at pre- and post- doctoral
students, nurses, allied medical personnel and physicians, 6) the
correlation and evaluation of biologic studies, and 7) the evaluation of
cancer control efforts to as early detection mechanisms. This research
effort will be conducted in cooperation with clinical and basic science
investigators at other SWOG institutions and the NCI whose collective
experience, information and wisdom will be used to design and conduct
clinical trials which will answer important questions in the therapy of
cancer.
The Ohio State University has been a member and active participant in the
Southwest Oncology Group for over thirty years. During this period OSU
has grown to be the leading contributor in patient accrual for all SWOG
institutions.
Tags: Combination Antineoplastic Therapy, Combination Chemotherapy, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Radiation Therapy, Neoplasm /cancer Surgery Adenocarcinoma, Antineoplastic, Azacitidine, Bone Marrow Transplantation, Breast Neoplasm, Cancer Prevention, Cis Platinum Compound, Clinical Study /trial, Colony Stimulating Factor, Cooperative Study, Cyclophosphamide, Dacarbazine, Deoxycoformycin, Doxorubicin, Drug Adverse Effect, Drug Interaction, Etoposide, Fluorouracil, Gastrointestinal Neoplasm, Hairy T Cell Leukemia, Head /neck Neoplasm, Hepatoma, Human Therapy Evaluation, Ifosfamide, Immunomodulator, Interferon Alpha, Interleukin 1, Interleukin 2, Interleukin 3, Leukemia, Lung Neoplasm, Lymphokine Activated Killer Cell, Melanoma, Melphalan, Mesothelioma, Metastasis, Mitomycin C, Mitoxantrone, Multidrug Resistance, Multiple Myeloma, Nasopharyngeal Neoplasm, Neoplasm /cancer Diagnosis, Neoplasm /cancer Education, Neoplasm /cancer Relapse /recurrence, Ovary Neoplasm, Pancreas Neoplasm, Passive Immunization, Prognosis, Renal Cell Carcinoma, Sarcoma, Splenectomy, Taxol, Therapy Compliance, Tumor Necrosis Factor Alpha, Urinary Tract Neoplasm, Uterus Neoplasm Human Subject
Tags: Combination Antineoplastic Therapy, Combination Chemotherapy, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Radiation Therapy, Neoplasm /cancer Surgery Adenocarcinoma, Antineoplastic, Azacitidine, Bone Marrow Transplantation, Breast Neoplasm, Cancer Prevention, Cis Platinum Compound, Clinical Study /trial, Colony Stimulating Factor, Cooperative Study, Cyclophosphamide, Dacarbazine, Deoxycoformycin, Doxorubicin, Drug Adverse Effect, Drug Interaction, Etoposide, Fluorouracil, Gastrointestinal Neoplasm, Hairy T Cell Leukemia, Head /neck Neoplasm, Hepatoma, Human Therapy Evaluation, Ifosfamide, Immunomodulator, Interferon Alpha, Interleukin 1, Interleukin 2, Interleukin 3, Leukemia, Lung Neoplasm, Lymphokine Activated Killer Cell, Melanoma, Melphalan, Mesothelioma, Metastasis, Mitomycin C, Mitoxantrone, Multidrug Resistance, Multiple Myeloma, Nasopharyngeal Neoplasm, Neoplasm /cancer Diagnosis, Neoplasm /cancer Education, Neoplasm /cancer Relapse /recurrence, Ovary Neoplasm, Pancreas Neoplasm, Passive Immunization, Prognosis, Renal Cell Carcinoma, Sarcoma, Splenectomy, Taxol, Therapy Compliance, Tumor Necrosis Factor Alpha, Urinary Tract Neoplasm, Uterus Neoplasm Human Subject
- Followup Grant: 5U10CA004920-35
- Followup Grant: 5U10CA004920-36
- Followup Grant: 5U10CA004920-38
Skeel, Roland T. Eastern Cooperative Oncology Group Studies
Grant: 2U10CA039227-05
Grant: 2U10CA039227-05
Abstract: The goal of this proposal is to improve knowledge of and treatment
of cancer through participation of the Medical College of Ohio
(MCO) with the Eastern Cooperative Oncology Group (ECOG). The
method used will be to continue the successful amalgam of the
scientific exPertise, organizational resources and outreach network
of the Medical College with the patient resources and enthusiasm
for clinical research in the Toledo community that has resulted in
a broadly based cohesive clinical research group in Toledo. The
success of the combined Toledo program is attested to by an annual
accrual of over 155 patients onto ECOG studies, extensive
multimodality scientific contributions to ECOG activities,
leadership in ECOG committees and participation in group meetings.
The core elements of MCO's participation and this proposal are the
scientific contributions by the radiotherapists, surgeons, and
medical oncologists, particularly in gastrointestinal neoplasms,
and the data management and quality control responsibility that the
MCO maintains for the entire Toledo program, including those
affiliates that are funded through the CCOP mechanism. The MCO
will contribute to the scientific design and critique of clinical
research in the ECOG through development of protocols for group-
wide use; leadership and participation in disease oriented,
modality, cancer control and health practices, and toxicity
committees performance of pilot studies based upon local expertise
and potential group-wide applicability; and timely publication of
group studies. New therapeutic modalities, such as interstitial
hyperthermia in conjunction with radiotherapy and chemotherapy,
photodynamictherapy and intraoperative radiation therapy will
continue to be developed and refined for integration into group-
wide clinical trials. Developmental studies in chemoprevention of
cancer will be brought to the ECOG through the Cancer Control and
Health Practices Committee research on cancer prevention in high
risk groups. The MCO will continue its active participation in
ECOG group-wide trials and coordinate and monitor the quality of
data from the entire Toledo Program. Through the design of
scientifically sound ECOG studies based upon pre-clinical and early
clinical trials at this institution and participation in group-wide
studies, the MCO will continue to contribute to improvement in the
care of patients with cancer.
Tags: Neoplasms Of Gastrointestinal System, Neoplastic Therapy, Cancer Radiotherapy, Neoplastic Therapy, Combination Antineoplastic Therapy, Therapy Evaluation, Human Antibiotics, Mitomycin, Drugs Adverse Effects, Folic Acid Antagonists, Methotrexate, Genetics, Cytogenetics, Halopyrimidines, Halouracil, Fluorouracil, Health Care Services, Case Finding And Outreach, Neoplasms Of Blood And Re System, Lymphoma, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Body Regions, Head And Neck, Neoplasms Of Gastrointestinal System, Esophagus Neoplasms, Neoplasms Of Gastrointestinal System, Rectum Growths, Neoplasms Of Pancreas, Neoplasms Of Reproductive System Female, Uterus Neoplasms, Cervix Neoplasms, Neoplasms Of Reproductive System, Breast Neoplasms, Neoplasms Of Respiratory System, Lung Neoplasms, Neoplasms Of Skeletal System, Bone Neoplasms, Neoplasms Of Skin, Melanoma, Neoplasms Of Urinary Tract, Urinary Bladder Neoplasms, Neoplasms Prevention And Control, Neoplasms Surgery, Neoplasms, Sarcoma, Neoplastic Disease Epidemiology-statistics, Cancer Risk, Neoplastic Therapy, Cancer Chemotherapy, Neoplastic Therapy, Cancer Photoradiation Therapy, Neoplastic Therapy, Cancer Radioisotope (nuclear) Therapy, Neoplastic Therapy, Thermotherapy, Neoplastic Transformation, Carcinogenesis, Chemical, Proteins, Binding Proteins, Lectins Non-plant, Radiosensitizers, Cooperative Study Biomedical Systems Automated, Computer Assisted Patient Care, Cell Sorting, Laser, Human, Clinical, Nucleic Acid Hybridization, In Situ Hybridization, Radioisotopes, Iodine, Radioisotopes, Technetium
Tags: Neoplasms Of Gastrointestinal System, Neoplastic Therapy, Cancer Radiotherapy, Neoplastic Therapy, Combination Antineoplastic Therapy, Therapy Evaluation, Human Antibiotics, Mitomycin, Drugs Adverse Effects, Folic Acid Antagonists, Methotrexate, Genetics, Cytogenetics, Halopyrimidines, Halouracil, Fluorouracil, Health Care Services, Case Finding And Outreach, Neoplasms Of Blood And Re System, Lymphoma, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Body Regions, Head And Neck, Neoplasms Of Gastrointestinal System, Esophagus Neoplasms, Neoplasms Of Gastrointestinal System, Rectum Growths, Neoplasms Of Pancreas, Neoplasms Of Reproductive System Female, Uterus Neoplasms, Cervix Neoplasms, Neoplasms Of Reproductive System, Breast Neoplasms, Neoplasms Of Respiratory System, Lung Neoplasms, Neoplasms Of Skeletal System, Bone Neoplasms, Neoplasms Of Skin, Melanoma, Neoplasms Of Urinary Tract, Urinary Bladder Neoplasms, Neoplasms Prevention And Control, Neoplasms Surgery, Neoplasms, Sarcoma, Neoplastic Disease Epidemiology-statistics, Cancer Risk, Neoplastic Therapy, Cancer Chemotherapy, Neoplastic Therapy, Cancer Photoradiation Therapy, Neoplastic Therapy, Cancer Radioisotope (nuclear) Therapy, Neoplastic Therapy, Thermotherapy, Neoplastic Transformation, Carcinogenesis, Chemical, Proteins, Binding Proteins, Lectins Non-plant, Radiosensitizers, Cooperative Study Biomedical Systems Automated, Computer Assisted Patient Care, Cell Sorting, Laser, Human, Clinical, Nucleic Acid Hybridization, In Situ Hybridization, Radioisotopes, Iodine, Radioisotopes, Technetium
- Followup Grant: 5U10CA039227-06
- Followup Grant: 5U10CA039227-07
- Followup Grant: 5U10CA039227-08
- Followup Grant: 5U10CA039227-09
Skeel, Roland T. Cooperative Oncology Group
Grant: 3U10CA039227-09S1
Grant: 3U10CA039227-09S1
Abstract: The goal of this proposal is to improve knowledge of and treatment
of cancer through participation of the Medical College of Ohio
(MCO) with the Eastern Cooperative Oncology Group (ECOG). The
method used will be to continue the successful amalgam of the
scientific exPertise, organizational resources and outreach network
of the Medical College with the patient resources and enthusiasm
for clinical research in the Toledo community that has resulted in
a broadly based cohesive clinical research group in Toledo. The
success of the combined Toledo program is attested to by an annual
accrual of over 155 patients onto ECOG studies, extensive
multimodality scientific contributions to ECOG activities,
leadership in ECOG committees and participation in group meetings.
The core elements of MCO's participation and this proposal are the
scientific contributions by the radiotherapists, surgeons, and
medical oncologists, particularly in gastrointestinal neoplasms,
and the data management and quality control responsibility that the
MCO maintains for the entire Toledo program, including those
affiliates that are funded through the CCOP mechanism. The MCO
will contribute to the scientific design and critique of clinical
research in the ECOG through development of protocols for group-
wide use; leadership and participation in disease oriented,
modality, cancer control and health practices, and toxicity
committees performance of pilot studies based upon local expertise
and potential group-wide applicability; and timely publication of
group studies. New therapeutic modalities, such as interstitial
hyperthermia in conjunction with radiotherapy and chemotherapy,
photodynamictherapy and intraoperative radiation therapy will
continue to be developed and refined for integration into group-
wide clinical trials. Developmental studies in chemoprevention of
cancer will be brought to the ECOG through the Cancer Control and
Health Practices Committee research on cancer prevention in high
risk groups. The MCO will continue its active participation in
ECOG group-wide trials and coordinate and monitor the quality of
data from the entire Toledo Program. Through the design of
scientifically sound ECOG studies based upon pre-clinical and early
clinical trials at this institution and participation in group-wide
studies, the MCO will continue to contribute to improvement in the
care of patients with cancer.
Tags: Chemoprevention, Combination Antineoplastic Therapy, Gastrointestinal Neoplasm, Human Therapy Evaluation, Neoplasm /cancer Radiation Therapy Bladder Neoplasm, Bone Neoplasm, Breast Neoplasm, Cancer Prevention, Cancer Risk, Cervix Neoplasm, Chemical Carcinogenesis, Clinical Trial, Cooperative Study, Cytogenetics, Drug Adverse Effect, Esophagus Neoplasm, Fluorouracil, Head /neck Neoplasm, Lectin, Lung Neoplasm, Lymphoma, Medical Outreach /case Finding, Melanoma, Mesothelioma, Methotrexate, Mitomycin, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Photoradiation Therapy, Neoplasm /cancer Radionuclide Therapy, Neoplasm /cancer Surgery, Neoplasm /cancer Thermotherapy, Pancreas Neoplasm, Radiosensitizer, Rectum Neoplasm, Sarcoma Computer Assisted Patient Care, Flow Cytometry, Human Subject, In Situ Hybridization, Iodine, Radionuclide, Technetium
Tags: Chemoprevention, Combination Antineoplastic Therapy, Gastrointestinal Neoplasm, Human Therapy Evaluation, Neoplasm /cancer Radiation Therapy Bladder Neoplasm, Bone Neoplasm, Breast Neoplasm, Cancer Prevention, Cancer Risk, Cervix Neoplasm, Chemical Carcinogenesis, Clinical Trial, Cooperative Study, Cytogenetics, Drug Adverse Effect, Esophagus Neoplasm, Fluorouracil, Head /neck Neoplasm, Lectin, Lung Neoplasm, Lymphoma, Medical Outreach /case Finding, Melanoma, Mesothelioma, Methotrexate, Mitomycin, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Photoradiation Therapy, Neoplasm /cancer Radionuclide Therapy, Neoplasm /cancer Surgery, Neoplasm /cancer Thermotherapy, Pancreas Neoplasm, Radiosensitizer, Rectum Neoplasm, Sarcoma Computer Assisted Patient Care, Flow Cytometry, Human Subject, In Situ Hybridization, Iodine, Radionuclide, Technetium
Clinical Trials
Condition: Malignant Mesothelioma
Intervention: Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis
More Information
Intervention: Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information
Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium
More Information
Intervention: Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium
More Information
Active, not recruiting Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
Condition: Malignant Mesothelioma
Intervention: Drug: dasatinib; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
More Information
Intervention: Drug: dasatinib; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
More Information
Condition: Lung Cancer; Malignant Mesothelioma; Metastatic Cancer; Precancerous/Nonmalignant Condition
Intervention: Procedure: bronchoscopic and lung imaging studies; Procedure: diagnostic bronchoscopy; Procedure: histopathologic examination; Procedure: optical coherence tomography
More Information
Intervention: Procedure: bronchoscopic and lung imaging studies; Procedure: diagnostic bronchoscopy; Procedure: histopathologic examination; Procedure: optical coherence tomography
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: pemetrexed disodium
More Information
Intervention: Drug: cisplatin; Drug: pemetrexed disodium
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: methotrexate; Drug: vinorelbine ditartrate; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
More Information
Intervention: Drug: cisplatin; Drug: methotrexate; Drug: vinorelbine ditartrate; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: epirubicin hydrochloride; Drug: gemcitabine hydrochloride
More Information
Intervention: Drug: epirubicin hydrochloride; Drug: gemcitabine hydrochloride
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium
More Information
Intervention: Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium
More Information
